AC Immune SA
(NASDAQ : ACIU)

( )
ACIU After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.50%43.970.9%$1186.44m
ABBVAbbVie, Inc. -0.22%107.121.9%$1023.77m
JNJJohnson & Johnson -0.23%164.480.7%$988.09m
MRKMerck & Co., Inc. 0.81%73.640.7%$914.30m
LLYEli Lilly & Co. -0.26%231.581.1%$588.95m
BMYBristol-Myers Squibb Co. -0.61%60.261.0%$575.61m
AZNAstraZeneca Plc 1.46%60.351.0%$353.10m
NVSNovartis AG -0.75%82.950.2%$156.40m
CRVSCorvus Pharmaceuticals, Inc. -3.27%6.800.7%$140.27m
GSKGlaxoSmithKline Plc -2.44%38.380.2%$135.32m
RGENRepligen Corp. -0.29%323.266.8%$123.14m
SNYSanofi -1.60%47.940.2%$122.20m
RPRXRoyalty Pharma Plc -0.08%37.100.1%$121.13m
VTRSViatris, Inc. 0.30%13.380.0%$107.54m
NVONovo Nordisk A/S -1.36%100.710.1%$101.76m

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.